RESUMEN
Polymerase chain reaction (PCR) tests cannot always detect the SARS-CoV-2 virus, possibly due to differences in sensitivity between sample types. Under these circumstances, immunochromatography may serve as an alternative method to detect anti-SARS-CoV-2 IgG antibodies that indicate a history of infection. In our analysis of patients with severe COVID-19 infection, we found that 14 of 19 serum samples were positive for IgG antibodies, whereas 6 of 10 samples from patients with asymptomatic or mild cases were negative. Two patients with immune thrombocytopenia who were treated with prednisolone experienced aggressive COVID-19-related respiratory failure and eventually died. Patients not in remission and those who received steroid-based chemotherapy had a higher risk of death, and patients with lymphoid malignancies including lymphoma and myeloma died in larger numbers than those with myeloid malignancies. A stricter cohorting strategy based on repeat PCR tests or isolation to a private room should be adopted in routine care in hematology departments to prevent viral spread to the environment.
Asunto(s)
COVID-19 , Infección Hospitalaria/prevención & control , Enfermedades Hematológicas/terapia , Anticuerpos Antivirales/sangre , Biomarcadores/sangre , COVID-19/complicaciones , COVID-19/diagnóstico , COVID-19/mortalidad , COVID-19/prevención & control , Femenino , Enfermedades Hematológicas/complicaciones , Enfermedades Hematológicas/mortalidad , Humanos , Inmunoensayo/métodos , Inmunoglobulina G/sangre , Control de Infecciones/métodos , Japón , Masculino , Aislamiento de Pacientes , Reacción en Cadena de la Polimerasa , Riesgo , SARS-CoV-2/inmunología , Índice de Severidad de la Enfermedad , Tasa de SupervivenciaRESUMEN
Patients with cancer are considered at high risk of acquiring coronavirus disease (COVID-19). To identify patients who are likely to be diagnosed with severe COVID-19, we analyzed the risk factors for mortality in patients admitted to the hematology department at our institute. The mortality rate of all patients was as high as 62% (21 of the 34 patients), and most of these patients had malignant malignancies. Patients before an achievement of remission had a 10.8-fold higher risk of death than those in remission. The group receiving chemotherapy with steroids had a shorter survival time and had an 8.3-fold higher risk of death than that receiving chemotherapy without steroids. During the COVID-19 pandemic, it is necessary to carefully monitor or follow-up patients with active diseases and patients receiving steroid-containing chemotherapy.
Asunto(s)
COVID-19 , Infección Hospitalaria , Glucocorticoides/efectos adversos , Enfermedades Hematológicas , COVID-19/complicaciones , Infección Hospitalaria/complicaciones , Femenino , Glucocorticoides/uso terapéutico , Enfermedades Hematológicas/complicaciones , Enfermedades Hematológicas/tratamiento farmacológico , Enfermedades Hematológicas/mortalidad , Humanos , Japón , Masculino , Factores de Riesgo , Índice de Severidad de la Enfermedad , Tasa de SupervivenciaRESUMEN
Haematology patients receiving chemo- or immunotherapy are considered to be at greater risk of COVID-19-related morbidity and mortality. We aimed to identify risk factors for COVID-19 severity and assess outcomes in patients where COVID-19 complicated the treatment of their haematological disorder. A retrospective cohort study was conducted in 55 patients with haematological disorders and COVID-19, including 52 with malignancy, two with bone marrow failure and one immune-mediated thrombotic thrombocytopenic purpura (TTP). COVID-19 diagnosis coincided with a new diagnosis of a haematological malignancy in four patients. Among patients, 82% were on systemic anti-cancer therapy (SACT) at the time of COVID-19 diagnosis. Of hospitalised patients, 37% (19/51) died while all four outpatients recovered. Risk factors for severe disease or mortality were similar to those in other published cohorts. Raised C-reactive protein at diagnosis predicted an aggressive clinical course. The majority of patients recovered from COVID-19, despite receiving recent SACT. This suggests that SACT, where urgent, should be administered despite intercurrent COVID-19 infection, which should be managed according to standard pathways. Delay or modification of therapy should be considered on an individual basis. Long-term follow-up studies in larger patient cohorts are required to assess the efficacy of treatment strategies employed during the pandemic.